Pharsight

Drug Patents Expiring in 2036

1. Agamree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690853 CATALYST PHARMS Non-hormonal steroid modulators of NF-κβ for treatment of disease
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 26, 2028
Orphan Drug Exclusivity(ODE-450) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 27 October, 2027

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION;ORAL

More Information on Dosage

AGAMREE family patents

Family Patents

2. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Jun, 2036

(12 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 09, 2025
M(M-61) Jul 09, 2024
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

3. Amvuttra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029
New Chemical Entity Exclusivity(NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

4. Arazlo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679116 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: NA

Dosage: LOTION;TOPICAL

How can I launch a generic of ARAZLO before it's drug patent expiration?
More Information on Dosage

ARAZLO family patents

Family Patents

5. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(11 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Jun, 2036

(12 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Strength(NS) Jul 09, 2024
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

6. Augtyro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10294242 BRISTOL Diaryl macrocycle polymorph
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11452725 BRISTOL Chiral diaryl macrocycles and uses thereof
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-455) Nov 15, 2030

Drugs and Companies using REPOTRECTINIB ingredient

Market Authorisation Date: 15 November, 2023

Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)

Dosage: CAPSULE;ORAL

More Information on Dosage

AUGTYRO family patents

Family Patents

7. Austedo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11564917 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11564917

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11446291

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Orphan Drug Exclusivity(ODE) Apr 03, 2024
Pediatric Exclusivity(PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

8. Austedo Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446291 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11564917 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US10959996

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11564917

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11446291

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11357772

(Pediatric)

TEVA Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

Family Patents

9. Bafiertam patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590095 BANNER LIFE SCIENCES Fumarate ester dosage forms
Mar, 2036

(11 years from now)

Drugs and Companies using MONOMETHYL FUMARATE ingredient

Market Authorisation Date: 28 April, 2020

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

BAFIERTAM family patents

Family Patents

10. Balversa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

US11684620 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-930) Jan 19, 2027
New Chemical Entity Exclusivity(NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemot...

Dosage: TABLET;ORAL

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

11. Baqsimi patents expiration

BAQSIMI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213487 AMPHASTAR PHARMS INC Nasal powder formulation for treatment of hypoglycemia
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

More Information on Dosage

BAQSIMI family patents

Family Patents

12. Biktarvy patents expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(12 years from now)

US11744802 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Feb 24, 2024
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
New Patient Population(NPP) Jun 18, 2022

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

13. Bludigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11845867 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 08, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 08 July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BLUDIGO family patents

Family Patents

14. Brilinta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(11 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-851) May 28, 2023
New Chemical Entity Exclusivity(NCE) Jul 20, 2016
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
Pediatric Exclusivity(PED) Nov 09, 2025
M(M-283) May 09, 2025
New Indication(I-848) Nov 05, 2023

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 20 July, 2011

Treatment: Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagre...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

15. Calquence patents expiration

CALQUENCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026
New Indication(I-817) Nov 21, 2022
New Chemical Entity Exclusivity(NCE) Oct 31, 2022
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with small lymphocytic leukemia

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

16. Calquence patents expiration

CALQUENCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents

17. Carospir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491166 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US11395828 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US11389461 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US9757394 CMP DEV LLC Spironolactone aqueous formulations
Oct, 2036

(12 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10493083 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

US10624906 CMP DEV LLC Spironolactone aqueous compositions
Oct, 2036

(12 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Market Authorisation Date: 04 August, 2017

Treatment: Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction; Carospir is indicated for treatment of nyha class iii-iv hea...

Dosage: SUSPENSION;ORAL

How can I launch a generic of CAROSPIR before it's drug patent expiration?
More Information on Dosage

CAROSPIR family patents

Family Patents

18. Combogesic Iv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11213498 HIKMA Aqueous formulation comprising paracetamol and ibuprofen
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 17, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient

Market Authorisation Date: 17 October, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

COMBOGESIC IV family patents

Family Patents

19. Cotellic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(12 years from now)

US11254649 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Jun, 2036

(12 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478400

(Pediatric)

GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Dec, 2036

(12 years from now)

US11254649

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
Dec, 2036

(12 years from now)

US10590102

(Pediatric)

GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
Pediatric Exclusivity(PED) Jan 28, 2026
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

20. Cyclophosphamide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993952 INGENUS PHARMS LLC Stable ready to use cyclophosphamide liquid formulations
Feb, 2036

(11 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 30 July, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage

CYCLOPHOSPHAMIDE family patents

Family Patents

21. Cysview Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10556010 PHOTOCURE ASA Neoadjuvant therapy for bladder cancer
Dec, 2036

(12 years from now)

US11311620 PHOTOCURE ASA Neoadjuvant therapy for bladder cancer
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 28, 2013
M(M-220) Feb 15, 2021

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2010

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

More Information on Dosage

CYSVIEW KIT family patents

Family Patents

22. Daurismo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 21, 2023
Orphan Drug Exclusivity(ODE-224) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of...

Dosage: TABLET;ORAL

More Information on Dosage

DAURISMO family patents

Family Patents

23. Delstrigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 30, 2023
New Indication(I-806) Sep 19, 2022
New Patient Population(NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage

DELSTRIGO family patents

Family Patents

24. Dexmedetomidine Hydrochloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(12 years from now)

US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(12 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 June, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEXMEDETOMIDINE HYDROCHLORIDE family patents

Family Patents

25. Docetaxel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398785 INGENUS PHARMS LLC Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
Mar, 2036

(11 years from now)

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 November, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DOCETAXEL family patents

Family Patents

26. Duobrii patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10251895 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US11648256 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US11679115 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage

DUOBRII family patents

Family Patents

27. Dyanavel Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590228 TRIS PHARMA INC Extended release amphetamine compositions
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 19, 2018

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: Method of treating attention deficit hyperactivity disorder

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR family patents

Family Patents

28. Elyxyb patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949990 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

US10799517 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

US10722456 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

US9572819 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

US10376527 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

US9795620 SCILEX HLDG Oral composition of celecoxib for treatment of pain
May, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2023

Drugs and Companies using CELECOXIB ingredient

Market Authorisation Date: 05 May, 2020

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

More Information on Dosage

ELYXYB family patents

Family Patents

29. Entresto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11058667 NOVARTIS PHARMS CORP Sacubitril-valsartan dosage regimen for treating heart failure
May, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually re...

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

30. Epaned patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040023 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10786482 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US9808442 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10039745 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11141405 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11173141 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10772868 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US9669008 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10154987 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of hypertension; Treatment of heart failure

Dosage: SOLUTION;ORAL

How can I launch a generic of EPANED before it's drug patent expiration?
More Information on Dosage

EPANED family patents

Family Patents

31. Esomeprazole Magnesium patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835488 DEXCEL Stable orally disintegrating pharmaceutical compositions
Dec, 2036

(12 years from now)

US10076494 DEXCEL Stable orally disintegrating pharmaceutical compositions
Dec, 2036

(12 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 20 October, 2020

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

ESOMEPRAZOLE MAGNESIUM family patents

Family Patents

32. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11827646 GENENTECH INC Compounds for treating spinal muscular atrophy
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
Orphan Drug Exclusivity(ODE-400) May 27, 2029
New Patient Population(NPP) May 27, 2025
M(M-270) Oct 03, 2026
New Chemical Entity Exclusivity(NCE) Aug 07, 2025

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

33. Exem Foam Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 07, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 08 November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: NA

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents

34. Ezallor Sprinkle patents expiration

Can you believe EZALLOR SPRINKLE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(11 years from now)

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

EZALLOR SPRINKLE family patents

Family Patents

35. Fintepla patents expiration

FINTEPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10947183 UCB INC Fenfluramine compositions and methods of preparing the same
Dec, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331

(Pediatric)

UCB INC Control system for control of distribution of medication
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-393) Mar 25, 2029
Pediatric Exclusivity(PED) Sep 25, 2029
New Product(NP) Jun 25, 2023
New Indication(I-887) Mar 25, 2025
Orphan Drug Exclusivity(ODE-312) Jun 25, 2027

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage

FINTEPLA family patents

Family Patents

36. Fyarro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10705070 AADI Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
Mar, 2036

(11 years from now)

US10973806 AADI Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 22, 2024
Orphan Drug Exclusivity(ODE-386) Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered ...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FYARRO family patents

Family Patents

37. Gavreto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2025
Orphan Drug Exclusivity(ODE-340) Dec 01, 2027
Orphan Drug Exclusivity(ODE-318) Sep 04, 2027
Orphan Drug Exclusivity(ODE-341) Dec 01, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 04 September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractor...

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

Family Patents

38. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213572 VERO BIOTECH INC Nitrogen dioxide storage cassette
Feb, 2036

(11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

39. Gloperba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383821 SCILEX PHARMS Colchicine drug-to-drug interactions
Nov, 2036

(12 years from now)

US10383820 SCILEX PHARMS Colchicine drug-to-drug interactions
Nov, 2036

(12 years from now)

US9907751 SCILEX PHARMS Composition and method of use of colchicine oral liquid
Nov, 2036

(12 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution

Dosage: SOLUTION;ORAL

How can I launch a generic of GLOPERBA before it's drug patent expiration?
More Information on Dosage

GLOPERBA family patents

Family Patents

40. Gvoke Hypopen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents
Apr, 2036

(12 years from now)

US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE HYPOPEN family patents

Family Patents

41. Gvoke Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE KIT family patents

Family Patents

42. Gvoke Pfs patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364 XERIS Methods for producing stable therapeutic formulations in aprotic polar solvents
Apr, 2036

(12 years from now)

US11590205 XERIS Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GVOKE PFS family patents

Family Patents

43. Ibrance patents expiration

IBRANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065250 PFIZER Solid dosage forms of palbociclib
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 03, 2020

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 03 February, 2019

Market Authorisation Date: 01 November, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

44. Imbruvica patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828259 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US9655857 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10213386 PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10010507 PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Mar, 2036

(11 years from now)

US10010507

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10828259

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US9655857

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

US10213386

(Pediatric)

PHARMACYCLICS LLC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Aug 02, 2024
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029
M(M-236) Jan 25, 2022
New Dosing Schedule(D-176) Aug 24, 2021
Pediatric Exclusivity(PED) Feb 24, 2026
New Chemical Entity Exclusivity(NCE) Nov 13, 2018
New Patient Population(NPP) Aug 24, 2025

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

45. Immphentiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471400 HIKMA Phenylephrine hydrochloride ready-to-use solution
Aug, 2036

(12 years from now)

US11213480 HIKMA Phenylephrine hydrochloride ready-to-use solution
Sep, 2036

(12 years from now)

Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 20 December, 2012

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

IMMPHENTIV family patents

Family Patents

46. Ingrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(12 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(12 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(12 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(12 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(12 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(12 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 11, 2022
Orphan Drug Exclusivity(ODE-440) Aug 18, 2030
New Indication(I-925) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 23 April, 2021

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

47. Inomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770570 MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
May, 2036

(12 years from now)

US9770570

(Pediatric)

MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-167) Oct 09, 2018
M(M-132) Dec 21, 2013
Pediatric Exclusivity(PED) Jun 21, 2014

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitric oxide as compared to the desired delivery concentra...

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage

INOMAX family patents

Family Patents

48. Invega Trinza patents expiration

INVEGA TRINZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 18, 2018
New Strength(NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA TRINZA before it's drug patent expiration?
More Information on Dosage

INVEGA TRINZA family patents

Family Patents

49. Jaypirca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10342780 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

US10695323 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464905 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

US10918622 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-424) Jan 27, 2030
New Chemical Entity Exclusivity(NCE) Jan 27, 2028
Orphan Drug Exclusivity(ODE-451) Dec 01, 2030

Drugs and Companies using PIRTOBRUTINIB ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

JAYPIRCA family patents

Family Patents

50. Kisqali patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 13, 2022
New Indication(I-784) Jul 18, 2021
New Indication(I-783) Jul 18, 2021
New Patient Population(NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage

KISQALI family patents

Family Patents

51. Kisqali Femara Co-pack (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506 NOVARTIS Ribociclib tablet
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 10, 2024
New Chemical Entity Exclusivity(NCE) Mar 13, 2022

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

Family Patents

52. Korlym patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166243 CORCEPT THERAP Optimizing mifepristone levels for cushing'S patients
Apr, 2036

(12 years from now)

US9943526 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients
Apr, 2036

(12 years from now)

US10166242 CORCEPT THERAP Optimizing mifepristone levels for Cushing's patients
Apr, 2036

(12 years from now)

US10660904 CORCEPT THERAP Optimizing mifepristone levels for cushing's patients
Apr, 2036

(12 years from now)

US10006924 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent cushing's syndrome
Aug, 2036

(12 years from now)

US10495650 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Aug, 2036

(12 years from now)

US9829495 CORCEPT THERAP Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 17, 2019
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

53. Kynmobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959943 SUMITOMO PHARMA AM Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

US10449146 SUMITOMO PHARMA AM Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage

KYNMOBI family patents

Family Patents

54. Lansoprazole patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077055 DEXCEL Orally disintegrating compositions
Apr, 2036

(12 years from now)

Drugs and Companies using LANSOPRAZOLE ingredient

Market Authorisation Date: 07 June, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

LANSOPRAZOLE family patents

Family Patents

55. Lenvima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090386 EISAI INC Method for suppressing bitterness of quinoline derivative
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 13, 2022
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
New Indication(I-734) May 13, 2019
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
New Indication(I-787) Aug 15, 2021
New Indication(I-807) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
M(M-269) Jul 21, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 13 February, 2019

Market Authorisation Date: 13 February, 2015

Treatment: Treatment with lenvima by administering lenvima as a suspension

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

56. Leqvio patents expiration

Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

57. Levothyroxine Sodium patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498 HIKMA Stabilized liquid formulation of levothyroxine
Jul, 2036

(12 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 17 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents

58. Levothyroxine Sodium patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 11 April, 2019

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents

59. Lexette patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407 MAYNE PHARMA Corticosteroid containing foam compositions and method of manufacture thereof
Nov, 2036

(12 years from now)

US10857159 MAYNE PHARMA Halobetasol foam composition and method of use thereof
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) May 24, 2021
New Patient Population(NPP) Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of LEXETTE before it's drug patent expiration?
More Information on Dosage

LEXETTE family patents

Family Patents

60. Lonhala Magnair Kit patents expiration

LONHALA MAGNAIR KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688518 SUMITOMO PHARMA AM Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Nov, 2036

(12 years from now)

US10744277 SUMITOMO PHARMA AM Aerosol delivery device and method of operating the aerosol delivery device
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

61. Lorbrena patents expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-847) Mar 03, 2024
Orphan Drug Exclusivity(ODE-218) Nov 02, 2025
Orphan Drug Exclusivity(ODE-219) Nov 02, 2025
Orphan Drug Exclusivity(ODE-217) Nov 02, 2025
New Chemical Entity Exclusivity(NCE) Nov 02, 2023
Orphan Drug Exclusivity(ODE-349) Mar 03, 2028

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 02 November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

Family Patents

62. Lotemax Sm patents expiration

LOTEMAX SM's oppositions filed in EPO
LOTEMAX SM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534395 BAUSCH AND LOMB INC Ophthalmic suspension composition
Jan, 2036

(11 years from now)

US10596107 BAUSCH AND LOMB INC Ophthalmic suspension composition
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Feb 22, 2022

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

How can I launch a generic of LOTEMAX SM before it's drug patent expiration?
More Information on Dosage

LOTEMAX SM family patents

Family Patents

63. Lytgobi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

Family Patents

64. Makena (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154562 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US9844558 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US10471075 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

US11304962 COVIS Methods of reducing risk of preterm birth
May, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Feb 03, 2018
Orphan Drug Exclusivity(ODE-7) Feb 03, 2018

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 15 July, 2016

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA (AUTOINJECTOR) before it's drug patent expiration?
More Information on Dosage

MAKENA (AUTOINJECTOR) family patents

Family Patents

65. Mavyret patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246866 ABBVIE Solid pharmaceutical compositions for treating HCV
Jun, 2036

(12 years from now)

US11246866

(Pediatric)

ABBVIE Solid pharmaceutical compositions for treating HCV
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-232) Apr 30, 2026
Orphan Drug Exclusivity(ODE-233) Apr 30, 2026
M(M-259) Apr 10, 2023
Pediatric Exclusivity(PED) Dec 10, 2028
M(M-230) Aug 06, 2021
New Patient Population(NPP) Apr 30, 2022
Orphan Drug Exclusivity(ODE-372) Jun 10, 2028
New Dosing Schedule(D-175) Sep 26, 2022
New Chemical Entity Exclusivity(NCE) Aug 03, 2022

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents

66. Melphalan Hydrochloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537520 APOTEX Stable liquid formulations of melphalan
Jun, 2036

(12 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 18 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

MELPHALAN HYDROCHLORIDE family patents

Family Patents

67. Miebo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357738 BAUSCH AND LOMB INC Semifluorinated compounds and their compositions
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 18, 2028

Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient

NCE-1 date: 19 May, 2027

Market Authorisation Date: 18 May, 2023

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

MIEBO family patents

Family Patents

68. Minolira patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517 EPI HLTH Pharmaceutical compositions for minocycline
Apr, 2036

(11 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

MINOLIRA family patents

Family Patents

69. Monoferric patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633489 PHARMACOSMOS AS Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
Jun, 2036

(12 years from now)

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: Treatment of iron deficiency anemia (dia) in adults patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney dise...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

MONOFERRIC family patents

Family Patents

70. Mounjaro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO family patents

Family Patents

71. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11338011 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US10695397 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US10238709 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11510963 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

US11052126 CHIESI Method of treating diseases
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents

72. Myrbetriq Granules patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058536 APGDI Pharmaceutical composition containing mirabegron
Mar, 2036

(11 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Sep 25, 2024
New Product(NP) Mar 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents

73. Nexlizet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

US11744816 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Product(NP) Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoi...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

Family Patents

74. Nextstellis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793760 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 15 April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

Family Patents

75. Nubeqa patents expiration

NUBEQA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 30, 2024
New Indication(I-900) Aug 05, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: 31 July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

Family Patents

76. Ocaliva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758549 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use
Apr, 2036

(12 years from now)

US10052337 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use
Apr, 2036

(12 years from now)

US10751349 INTERCEPT PHARMS INC Compositions of obeticholic acid and methods of use
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) May 27, 2023
Orphan Drug Exclusivity(ODE-119) May 27, 2023
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using OBETICHOLIC ACID ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca

Dosage: TABLET;ORAL

How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage

OCALIVA family patents

Family Patents

77. Odomzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10266523 SUN PHARM Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 24, 2020

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ODOMZO family patents

Family Patents

78. Olpruva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433041 ACER Palatable compositions including sodium phenylbutyrate and uses thereof
Oct, 2036

(12 years from now)

US11154521 ACER Palatable compositions including sodium phenylbutyrate and uses thereof
Oct, 2036

(12 years from now)

US11202767 ACER Methods of treating urea cycle disorders and maple syrup urine disease
Oct, 2036

(12 years from now)

Drugs and Companies using SODIUM PHENYLBUTYRATE ingredient

Market Authorisation Date: 22 December, 2022

Treatment: Treatment of a urea cycle disorder involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

OLPRUVA family patents

Family Patents

79. Omeprazole patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835488 DEXCEL Stable orally disintegrating pharmaceutical compositions
Dec, 2036

(12 years from now)

US10076494 DEXCEL Stable orally disintegrating pharmaceutical compositions
Dec, 2036

(12 years from now)

Drugs and Companies using OMEPRAZOLE ingredient

Market Authorisation Date: 05 July, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

OMEPRAZOLE family patents

Family Patents

80. Onivyde patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456360 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

US10993914 IPSEN INC Stabilizing camptothecin pharmaceutical compositions
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-99) Oct 22, 2022
Orphan Drug Exclusivity(ODE-463) Feb 13, 2031
Orphan Drug Exclusivity(ODE) Oct 22, 2022
New Product(NP) Oct 22, 2018

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage

ONIVYDE family patents

Family Patents

81. Opfolda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278601 AMICUS THERAP US Augmented acid alpha-glucosidase for the treatment of Pompe disease
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2026

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 28 September, 2023

Treatment: The treatment of pompe patients

Dosage: CAPSULE;ORAL

More Information on Dosage

OPFOLDA family patents

Family Patents

82. Orgovyx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350170 SUMITOMO PHARMA Solid preparation
Feb, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

Family Patents

83. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10682351 ABBVIE Methods of administering elagolix
Sep, 2036

(12 years from now)

US10537572 ABBVIE Methods of administering elagolix
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole; Management of moderate to severe pain associated with endometriosis using...

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

84. Orserdu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11819480 STEMLINE THERAP Methods for treating cancer
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORSERDU family patents

Family Patents

85. Ortikos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172802 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(12 years from now)

US9707182 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(12 years from now)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 13 June, 2019

Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

ORTIKOS family patents

Family Patents

86. Oxbryta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET;ORAL

More Information on Dosage

OXBRYTA family patents

Family Patents

87. Pemfexy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793813 EAGLE PHARMS Pemetrexed formulations
Feb, 2036

(11 years from now)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PEMFEXY family patents

Family Patents

88. Proair Digihaler patents expiration

PROAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 12, 2018
New Patient Population(NPP) Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

89. Procysbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 22, 2024
Pediatric Exclusivity(PED) Jun 22, 2025
M(M-216) Dec 22, 2020

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL; CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage

PROCYSBI family patents

Family Patents

90. Rinvoq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11186584 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11718627 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11773105 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US9951080 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10981923 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11680069 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11661425 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11198697 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10202393 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11535625 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10344036 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10519164 ABBVIE Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10981924 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11524964 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11780848 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11512092 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11365198 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10550126 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11795175 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10995095 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11535624 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11535626 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11773106 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11767326 ABBVIE Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)